CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative...
Pharmaceutical
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
Apexigen Announces Review of Strategic Alternatives and Restructuring
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative...
Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023
MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass.,...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a...
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Feb. 24, 2023...
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y.,...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ETNEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) --...
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the...
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0...
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...